Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,189-1,200 of 4,306
Drug study icon
CompletedNCT01994473

Safety study of SEP-363856 in schizophrenia

This study is completed in the United States. It is testing SEP-363856 for schizophrenia.

Multiple locations, including Glendale
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT00620568

Study Evaluating Multiple Ascending Dose in Schizophrenia Patients

This summary needs review. Please check the official study record and contact the research team for details.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 50 Years
Countries
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Schizophrenia
Drug study icon
CompletedNCT01499563

a Novel Antipsychotic ITI-007 in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT00711269

SM-13496 (Lurasidone HCl) in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Tokyo, Etc.
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 74 Years
Countries
Japan, South Korea, Taiwan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
Drug study icon
Active Not RecruitingNCT06442462

SPG302 in Adults With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Garden Grove
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Australia
Sponsor
Spinogenix
Condition
Schizophrenia
Behavioral study icon
CompletedNCT05838625

Two Digital Therapeutics for Experiential Negative Symptoms of Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Chandler
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralOver 18 Years
Countries
United States
Sponsor
Click Therapeutics, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT06572449

Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in schizophrenia

This study is completed in the United States. It is testing Slowly Increasing Dose and Food Effect of KarXT for schizophrenia.

Multiple locations, including Los Alamitos
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.